Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas
Executive Summary
Celgene is on a course to transition from a company centered mainly on the multiple myeloma blockbuster Revlimid to a diversified biotech over the next five years. That's the strategy management laid out for investors during an R&D day in New York April 8
You may also be interested in...
Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach
Absent proof of an overall survival benefit, new data suggesting a link between longer-term use of Celgene Corp.’s blockbuster Revlimid and secondary malignancies in multiple myeloma may encourage a cautious approach to maintenance treatment, threatening a major expansion for the drug.
Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach
Absent proof of an overall survival benefit, new data suggesting a link between longer-term use of Celgene Corp.’s blockbuster Revlimid and secondary malignancies in multiple myeloma may encourage a cautious approach to maintenance treatment, threatening a major expansion for the drug.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Highlights from the Q2 2010 review of pharmaceutical and biotechnology dealmaking: Biopharma companies raised a total of $3.4bn through 96 financings. Twenty-one acquisitions together reached $20.2bn, thanks to five deals each exceeding $3 billion - in aggregate accounting for 91% of the M&A total. The alliance volume was up to 115 transactions for a total of $2.8 billion in pre-commercialization money, with seven deals surpassing the $100 million mark.